{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:27:11Z","timestamp":1784759231898,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.genhosppsych.2012.04.009","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T20:10:42Z","timestamp":1339704642000},"page":"213.e5-213.e7","source":"Crossref","is-referenced-by-count":5,"title":["A case of paliperidone-palmitate-induced tardive dyskinesia"],"prefix":"10.1016","volume":"35","author":[{"given":"John","family":"Lally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fintan","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev.me.35.020184.003133","article-title":"Tardive dyskinesia","volume":"35","author":"Tarsy","year":"1984","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d (2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00421217","article-title":"Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia","volume":"34","author":"Gerlach","year":"1974","journal-title":"Psychopharm."},{"issue":"2","key":"10.1016\/j.genhosppsych.2012.04.009_bb0025","first-page":"CD000205","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database Sys Rev"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0006-3223(93)90044-E","article-title":"Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia","volume":"34","author":"Miller","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(99)00021-3","article-title":"The treatment of tardive dyskinesia-systematic review and meta-analysis","volume":"39","author":"Soares","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0040","first-page":"190","article-title":"Tardive dyskinesia: a task force report of the American Psychiatric Association","volume":"44","author":"American Psychiatric Association","year":"1993","journal-title":"Hosp Community Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.174.1.23","article-title":"Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol","volume":"174","author":"Beasley","year":"1999","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1 year studies","volume":"161","author":"Cu","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0060","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1517\/14656566.2010.495387","article-title":"Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania","volume":"11","author":"Canuso","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0065","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.genhosppsych.2012.04.009_bb0075","first-page":"781","article-title":"Abnormal Involuntary Movement Scale (AIMS)","volume":"24","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/NDT.S17177","article-title":"Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia","volume":"7","author":"Gopal","year":"2011","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0090","doi-asserted-by":"crossref","unstructured":"Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res. 116; 17\u2013117","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0095","article-title":"Oral-paliperidone-induced tardive dyskinesia: a case report","author":"Han-Ting","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/JCP.0b013e318219263d","article-title":"Paliperidone-related rabbit syndrome","volume":"31","author":"Teng","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0105","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.pnpbp.2004.05.016","article-title":"Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomised to blinded dose reduction periods","author":"Kinon","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psych"},{"key":"10.1016\/j.genhosppsych.2012.04.009_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00004714-199902000-00019","article-title":"Olanzapine in the treatment of tardive dyskinesia: a report of two cases","volume":"19","author":"Soutullo","year":"1999","journal-title":"J Clin Psychopharmacol"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834312001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834312001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T00:39:33Z","timestamp":1561855173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834312001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0163834312001429"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.04.009","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}